Previous 10 | Next 10 |
Corbus Pharmaceuticals (CRBP): Q1 GAAP EPS of -$0.14 in-line.Revenue of $0.65M (-63.1% Y/Y) misses by $0.11M.Cash, cash equivalents and investments were $125 million as of March 31, 2021. During the first quarter of 2021, the Company raised $58.9 million in net proceeds from the Companyȁ...
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022 Corbus is actively engaging with potential partners to expand ...
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announc...
Corbus Pharmaceuticals (CRBP) announces that the last participant was enrolled in a Phase 2 study of lenabasum for the treatment of systemic lupus erythematosus ((SLE)), a systemic autoimmune disease affecting more than 200K Americans.The 16-week, U.S., multi-center, first-in-p...
First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLE Study sponsored and funded by the Na s tional Institute of Allergy and Infectious Diseases through the Autoimmunity Centers of Excellence (ACE...
Biotech Penny Stocks to Watch This Month Penny stocks are well-known for their higher level of risk in the stock market today. The problem here is that the risk can quickly deter traders and investors from even exploring the topic. This is why research is so important. Just taking a dar...
Top-line results are expected for Lenabasum in phase 3 for dermatomyositis shortly. Management believes an inflection point could be on the cards. We remain long and will formulate a strategy as we close in on the binary event. For further details see: Corbus: Assessing ...
Corbus Pharmaceuticals (CRBP) announces that the last subject completed the final visit in the double-blind, placebo-controlled part of the company’s late-stage DETERMINE study of lenabasum for the treatment of dermatomyositis, a rare and life-threatening autoimmune disease.T...
Topline data on schedule for Q2 2021 Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU, and Japan There is a significant need for safer and more effective treat...
Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...
News, Short Squeeze, Breakout and More Instantly...
Corbus Pharmaceuticals Holdings Inc. Company Name:
CRBP Stock Symbol:
NASDAQ Market:
Corbus Pharmaceuticals Holdings Inc. Website:
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-07-16 13:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...